Congress offers $40B+ in tax breaks to pharma firms for domestic manufacturing

What it does

This bill creates a new federal tax credit system to incentivize medical device and pharmaceutical manufacturing in economically distressed U.S. zones. Companies that locate or expand medical manufacturing facilities in designated poor areas receive credits worth 40% of wages, employee benefits, and equipment depreciation; companies that source components from distressed zones receive credits worth 30% of those purchases. Enhanced credits (50–60%) apply to facilities that relocate production from foreign countries deemed supply-chain risks or that produce population-health products for vulnerable groups. The bill also expands federal authority to develop and distribute medicines targeting vulnerable populations during epidemics.

Why we flagged it

The bill's core mechanism is a targeted tax credit system (40–60% of wages, benefits, and capital costs) for pharmaceutical and medical-device manufacturers locating or sourcing in economically distressed areas. The secondary public-health provisions (population-health product development and vulnerable-population protections) are supportive but subordinate to the tax incentive structure.

What the text implies

• Tax credits are uncapped and available to any company meeting the facility/product definition, creating potential for large corporations to claim credits on existing operations or marginal expansions, with no requirement to demonstrate net job creation or supply-chain improvement.
• The 'related person' credit (5% vs. 30% for unrelated suppliers) may incentivize vertical integration and captive supply chains rather than competitive regional supplier networks, concentrating market power.
• Designation of 'economically distressed zones' is discretionary (Secretary and Commerce Secretary approval required for the 25% poverty threshold category), creating political leverage and potential for favoritism in zone selection.
• The bill expands HHS authority to identify 'population health products' and direct federal agencies to distribute them, potentially bypassing normal FDA approval timelines or market competition for certain medicines.
• No sunset clause or performance metrics (e.g., job creation, supply-chain resilience, price controls) are specified; credits may persist indefinitely even if manufacturing does not materialize or supply-chain risk remains.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill offers a genuine public benefit: incentivizing domestic medical manufacturing in poor regions could create jobs, strengthen supply-chain resilience, and improve access to medicines for vulnerable populations during health crises. However, the tax credits are substantial (40–60% of wages and capital costs) and run to private pharmaceutical and device manufacturers with no explicit cap, clawback, or performance requirement—meaning taxpayers subsidize private profits with uncertain return

Who stands to gain

• pharmaceutical manufacturers
• medical device manufacturers
• biologics producers
• contract manufacturers in distressed zones

Named in the bill

Internal Revenue Service, Department of Commerce, Department of Health and Human Services, FDA, Centers for Medicare & Medicaid Services, Department of Defense, Department of Veterans Affairs, U.S. Trade Representative, pharmaceutical industry, medical device industry

Where it stands

10 cosponsors: 6 Republicans, 4 Democrats.

• Apr 28, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 28, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $570,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Nicole Malliotakis, the sponsor, reported $1,140,250 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• Cencora, Inc. — $510,000 on 1 filing
• Puerto Rico Fiscal Agency and Financial Advisory Authority (aafaf) — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.